Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1989-5-26
|
| pubmed:abstractText |
The known properties of xamoterol, a partial beta 1-agonist, provide a basis to pharmacologically modulate cardiac responses to variations in sympathetic tone. Haemodynamic variables were assessed at rest and on exercise before and after intravenous xamoterol (0.2 mg kg-1), in 30 patients with mild to moderate cardiac failure. Xamoterol produced significant improvements in resting cardiac index (2.51 +/- 0.15 to 2.80 +/- 0.14 l min-1 m-2; P less than 0.001), stroke volume (62 +/- 4 to 75 +/- 5 mljbeat-1; P less than 0.001) and stroke work index (42.4 +/- 3.6 to 47.7 +/- 3.9 gm beat-1 m-2; P less than 0.01). This occurred despite a significant reduction in heart rate (78 +/- 3 to 74 +/- 2 beats min-1; P less than 0.05). There were also significant reductions in systemic vascular resistance (1990 +/- 141 to 1669 +/- 112 dynes s-1 cm-5; P less than 0.01) and double product (1146 +/- 46 to 1051 +/- 41 mmHg min-1 x 10(-1); P less than 0.05), with no significant changes in systolic blood pressure, pulmonary wedge pressure or ejection fraction. Xamoterol significantly attenuated the heart rate response to exercise (112 +/- 4 to 97 +/- 3 beats min-1; P less than 0.001), with no impairment in the expected exercise induced increase in cardiac index. This was due to the significant increase in stroke volume from 81 +/- 6 to 95 +/- 7 ml beat-1 (P less than 0.001). There were no significant changes in resting or exercise noradrenaline levels.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0195-668X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
227-34
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2565233-Adrenergic beta-Agonists,
pubmed-meshheading:2565233-Adult,
pubmed-meshheading:2565233-Aged,
pubmed-meshheading:2565233-Blood Pressure,
pubmed-meshheading:2565233-Cardiac Output,
pubmed-meshheading:2565233-Drug Evaluation,
pubmed-meshheading:2565233-Exercise Test,
pubmed-meshheading:2565233-Female,
pubmed-meshheading:2565233-Heart Failure,
pubmed-meshheading:2565233-Heart Rate,
pubmed-meshheading:2565233-Hemodynamics,
pubmed-meshheading:2565233-Humans,
pubmed-meshheading:2565233-Injections, Intravenous,
pubmed-meshheading:2565233-Male,
pubmed-meshheading:2565233-Middle Aged,
pubmed-meshheading:2565233-Propanolamines,
pubmed-meshheading:2565233-Pulmonary Wedge Pressure,
pubmed-meshheading:2565233-Stroke Volume,
pubmed-meshheading:2565233-Time Factors,
pubmed-meshheading:2565233-Vascular Resistance,
pubmed-meshheading:2565233-Xamoterol
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure.
|
| pubmed:affiliation |
Department of Cardiovascular Medicine, University of Birmingham, East Birmingham Hospital, U.K.
|
| pubmed:publicationType |
Journal Article
|